Shoulder Innovations Q2 Earnings Call Highlights

Impact · against what's priced in

Shoulder Innovations (SI) is demonstrating strong commercial execution with a 56% revenue jump and an upgraded full-year outlook. The narrowing net loss and expanded liquidity via $50 million in debt facilities significantly lower near-term financial risk, while the 2027 robotics timeline provides a long-term growth optionality.

SI+0.60

No priced-in read yet

In context

The company raised its 2026 revenue outlook to $67M-$69M and reported a 56% YoY increase in Q2 revenue to $17.2M, driven by surgeon adoption and market share gains from incumbents.

Read from the article alone

• guidance
• revenue growth
• earnings
• healthcare
• SI
• fda
• medical devices
• orthopedics
• robotic surgery

Search tags